Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125882072 | 12588207 | 2 | F | 19970114 | 20160822 | 20160725 | 20160901 | EXP | CA-GILEAD-2016-0224316 | GILEAD | 69.00 | YR | E | M | Y | 0.00000 | 20160901 | MD | CA | CA |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125882072 | 12588207 | 1 | PS | EMTRICITABINE | EMTRICITABINE | 1 | Unknown | U | 21500 | CAPSULE | |||||||||
125882072 | 12588207 | 2 | SS | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Unknown | U | 0 | TABLET | |||||||||
125882072 | 12588207 | 3 | SS | LAMIVUDINE. | LAMIVUDINE | 1 | Unknown | UNK | U | 0 | |||||||||
125882072 | 12588207 | 4 | SS | LAMIVUDINE. | LAMIVUDINE | 1 | U | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125882072 | 12588207 | 1 | HIV infection |
125882072 | 12588207 | 2 | HIV infection |
125882072 | 12588207 | 3 | HIV infection |
125882072 | 12588207 | 4 | Hepatitis B |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125882072 | 12588207 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125882072 | 12588207 | Viral mutation identified |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125882072 | 12588207 | 3 | 1995 | 0 |